日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Nationwide Survival Impact of Bevacizumab Under National Reimbursement for Advanced Cervical Cancer in South Korea

韩国国家医保覆盖下贝伐单抗对晚期宫颈癌患者全国生存率的影响

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers18020346
Kim, Junhwan; Jang, Jieun; Tewari, Krishnansu S; Kim, Kyung Su; Kang, Hyun-Cheol; Kang, Sokbom
宫颈癌
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Population-Level Trends in Lifestyle Factors and Early-Onset Breast, Colorectal, and Uterine Cancers

生活方式因素与乳腺癌、结直肠癌和子宫癌早发的人群趋势

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers18010167
Ayoub, Natalie L; Francoeur, Alex A; Chang, Jenny; Tran, Nathan; Tewari, Krishnansu S; Kapp, Daniel S; Bristow, Robert E; Chan, John K
肿瘤
肠癌
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials

对目前已获批准用于治疗晚期或复发性子宫内膜癌的免疫疗法方案进行成本效益分析：NRG-GY 018、RUBY 和 DUO-E 试验的分析

期刊:Gynecologic Oncology Reports
影响因子:1.3
doi:10.1016/j.gore.2026.102050
Francoeur, Alex A; Liang, Su-Ying; File, Brittany; Choi, Eunji; Brameld, Max; Richardson, Michael T; Johnson, Caitlin R; Kapp, Daniel S; Tewari, Krishnansu S; Chan, John K
肿瘤
子宫内膜癌
肿瘤免疫
免疫/内分泌
发表日期：2026
文献求助 收藏

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma

NRG258 是一项随机 III 期试验，比较放化疗与单纯化疗治疗局部晚期子宫内膜癌的疗效，本研究的长期随访和总生存期如下：

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.24.01121
Matei, Daniela E; Enserro, Danielle M; Randall, Marcus E; Mutch, David; Small, William; DiSilvestro, Paul A; Spirtos, Nick M; O'Malley, David M; Cantuaria, Guilherme H; Michelin, David; Waggoner, Steven; Shahin, Mark; Guntupalli, Saketh; Lara, Olivia; Ueland, Frederick R; Warshal, David; Bonebrake, Albert; Tewari, Krishnansu S; Tan, Annie; Powell, Matthew A; Walker, Joan L; Santin, Alessandro D; Kim, Jong Hyeok; Miller, David S
肿瘤
子宫内膜癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Drug discovery in advanced and recurrent endometrial cancer: Recent advances

晚期和复发性子宫内膜癌药物研发：最新进展

期刊:Oncology Research
影响因子:4.1
doi:10.32604/or.2025.061120
Francoeur, Alex A; Ayoub, Natalie; Greenberg, Danielle; Tewari, Krishnansu S
肿瘤
子宫内膜癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol

前瞻性评估腹膜恶性细胞学在子宫内膜癌预后中的意义：一项基于 GOG-210 方案的 NRG 肿瘤/妇科肿瘤协作组研究

期刊:Gynecologic Oncology
影响因子:4.1
doi:10.1016/j.ygyno.2025.08.029
Matsuo, Koji; Enserro, Danielle M; Wright, Jason D; Roman, Lynda D; Powell, Matthew A; Miller, David S; Nagel, Christa I; Thaker, Premal H; Mannel, Robert S; Stuckey, Ashley R; Guntupalli, Saketh R; Sukumvanich, Paniti; Geller, Melissa A; Vargas, Roberto; Konecny, Gottfried E; Warshal, David P; Tewari, Krishnansu S; Spirtos, Nick M; Pothuri, Bhavana; Creasman, William T; Mutch, David G
细胞生物学
肿瘤
子宫内膜癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis

帕博利珠单抗联合化疗（加或不加贝伐珠单抗）治疗东亚持续性、复发性或转移性宫颈癌患者：KEYNOTE-826最终分析结果

期刊:Journal of Gynecologic Oncology
影响因子:3.7
doi:10.3802/jgo.2025.36.e110
Kim, Yong-Man; Nishio, Shin; Kim, Se Ik; Hasegawa, Kosei; Dubot, Coraline; Cáceres, M Valeria; Tewari, Krishnansu S; Lorusso, Domenica; Lee, Jeong-Won; Liou, Wen-Shiung; Li, Kan; Tekin, Cumhur; Colombo, Nicoletta; Monk, Bradley J
宫颈癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives

多斯利单抗在晚期和复发性子宫内膜癌中的临床应用：患者选择和展望

期刊:Cancer Management and Research
影响因子:2.6
doi:10.2147/CMAR.S341469
Bujnak, Alyssa C; File, Brittany; Tewari, Krishnansu S
肿瘤
子宫内膜癌
肿瘤免疫
发表日期：2025
文献求助 收藏

A pragmatic randomized trial to compare strategies for implementing primary HPV testing for routine cervical cancer screening in a large healthcare system

一项务实的随机试验，旨在比较在大型医疗保健系统中实施HPV初筛作为宫颈癌常规筛查策略的不同方法。

期刊:Implementation Science
影响因子:
doi:10.1186/s13012-025-01432-9
Chao, Chun R; Cannizzaro, Nancy; Hahn, Erin E; Shen, Ernest; Hsu, Chunyi; Ngo-Metzger, Quyen; Gould, Michael K; Munoz-Plaza, Corrine E; Kanter, Michael H; Wride, Patricia; Ajamian, Lena H; Hodeib, Melissa; Broder, Benjamin I; Curiel, Ivette T; Castaneda, Alicia; Ong, Stephanie K; Tewari, Krishnansu; Eskander, Ramez N; Tewari, Devansu; Mittman, Brian S
宫颈癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial

帕博利珠单抗或安慰剂联合化疗（含或不含贝伐珠单抗）治疗持续性、复发性或转移性宫颈癌：KEYNOTE-826随机临床试验的亚组分析

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2023.5410
Tewari, Krishnansu S; Colombo, Nicoletta; Monk, Bradley J; Dubot, Coraline; Cáceres, M Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yañez, Eduardo; Gümüs, Mahmut; Olivera Hurtado de Mendoza, Mivael; Samouëlian, Vanessa; Castonguay, Vincent; Arkhipov, Alexander; Tekin, Cumhur; Li, Kan; Toker, Sarper; Keefe, Stephen M; Lorusso, Domenica
宫颈癌
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏